Clinical trial
Efficacy of Treating First Episode Psychosis With Folic Acid,B12 and B6 in…
NCT00202280 · Melbourne Health, Other · Completed
Key facts
| NCT number | NCT00202280 |
|---|---|
| Title | Efficacy of Treating First Episode Psychosis With Folic Acid,B12 and B6 in Addition to Antipsychotic Medication |
| Official title | VIP (Vitamins In Psychosis) Study. A Randomized Double Blind Placebo Controlled Trial of the Effects of Vitamin B12, B6 and Folic Acid Augmentation on Cognition and Symptoms in Early Psychosis. |
| Lead sponsor | Melbourne Health, Other |
| Collaborators | Stanley Medical Research Institute |
| Status | Completed |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | First Episode Psychosis |
| Intervention type | Drug |
| Interventions | Folic Acid 5mg, Vitamin B12 0.4mg and B6 50mg |
| Enrollment | 120 |
| Start date | Sep 1, 2004 |
| Primary completion | Sep 1, 2006 |
| Completion | Jun 1, 2009 |
| First posted | Sep 20, 2005 |
| Last update posted | Nov 20, 2015 |
| Countries | Australia |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: